ByHeart Files IPO Prospectus: Redefining Infant Formula with FDA-Approved, Breast Milk-Inspired Innovation

In February 2022, Abbott recalled certain products under the Similac, Alimentum, and EleCare brands and shut down its plant in Sturgis, Michigan, delivering the final blow that exacerbated the “infant formula shortage.”

In fact, the U.S. infant formula market is monopolized by four companies—Abbott Nutrition, Mead Johnson Nutrition, Nestlé USA, and Perrigo—which together control 90% of the nation’s formula supply. Among them, Abbott holds a dominant position. According to 2011 data from the U.S. Department of Agriculture, Abbott already accounted for approximately 43% of the national market share a decade ago.

Abbott’s recent recall has ignited the U.S. infant formula crisis, revealing a “new entrant” that successfully broke into the oligopolistic market—ByHeart , it is the only infant formula manufacturer that has developed its formulation entirely from scratch and has completed the largest and most comprehensive clinical trials for U.S. infant formula brands. Meanwhile, it has been highly sought after by a host of investors; in 2020 and 2021,Has secured a total of $160 million in financing.

ByHeart’s founding team consists of a brother and sister, with the older brotherRon BelldegrunSpent eight years at Visium Asset Management, a healthcare-focused investment fund, and was a member of the Vagelos Program in Life Sciences and Management at the Wharton School of the University of Pennsylvania. Conducted research on a new infant formula guided by studies on breast milk. Younger sisterMia Funtserved as Director of Global Business Development and Global Product Marketing at AOL and Verizon, possessing extensive sales experience and strategic planning capabilities.

ByHeart Co-founders Ron Belldegrun and Mia Funt. Image source: ByHeart official website

“We know what it takes to drive real innovation in the infant formula sector,” Belldegrun mentioned in an interview, noting that most market players collaborate with Perrigo, which allows for rapid product launches, butStartups, however, are unable to control the formulations or raw materials they desire., can only become a pure marketing company.

To incorporate the latest academic research on breast milk into their formula, they leveraged their combined expertise in consumer technology and life sciences, exercising full control over the supply chain from the ground up, and2016Officially established ByHeart.

Subsequently, ByHeart rapidly assembled aA Professional Team of Pediatric Nutritionists and Breast Milk Researchers, to enhance ByHeart’s product research and development capabilities. R&D personnel who joined during this period include J. Bruce German, Director of the Foods for Health Institute at the University of California, Davis; Bo Lönnerdal, Professor of Nutrition and Internal Medicine at the University of California, Davis; and Steven H. Zeisel, Professor of Nutrition and Pediatrics at the University of North Carolina.12 casesExpert.

The FDA imposes stringent regulations on infant formula. Due to technical issues such as labeling requirements, the volume of imported infant formula in the United States is very limited, with tariffs reaching as high as 17%. Historically, 98% of the infant formula consumed by babies and toddlers in the U.S. has been produced by domestic manufacturers. Throughout this process, the supply chain plays a crucial role in ensuring that manufacturers can continuously deliver products.

Beyond R&D and manufacturing processes, ByHeart also needsA Complete Supply Chain. To this end, in 2019, ByHeart acquired a manufacturing facility in Reading, Pennsylvania, that produces infant and toddler nutrition products. The facility is certified Kosher, grass-fed, organic, and Safe Quality Food (SQF).

Finally, ByHeart spent five years launching its production facilities, establishing its supply chain, completing clinical trials, and obtaining regulatory approval. Finally, in 2021, ByHeart completed the300 Infantsclinical trials, becoming the first new infant formula manufacturer in the United States in 15 years and one of only five such manufacturers currently operating in the country.

Currently, infant formula is trending toward the premium segment. To make products more closely resemble breast milk, key components found in breast milk—such as OPO (1,3-dioleoyl-2-palmitoyl glycerol), lactoferrin, prebiotics (HMOs, human milk oligosaccharides), and omega-3 and omega-6 fatty acids—are being incorporated.

among whichLactoferrin, also known as lactoferrin, is a multifunctional transferrin naturally present in human and bovine milk. As an antimicrobial and antiviral component, lactoferrin plays a crucial role in the development of infants' immune systems. It also facilitates iron absorption from breast milk for babies, and infant formula containing lactoferrin is categorized as premium formula.

In 2021, ByHeart launched the first U.S.Patented Protein Blend Formula of Lactoferrin and α-Lactalbumin, and hailed it as the infant formula “closest to breast milk.”

ByHeart Formula Nutritional Comparison, Image Source: ByHeart Official Website

ByHeart’s infant formula demonstrates three advantages: the first is alpha-lactalbumin and lactoferrinThe content increased by 60%., which helps infants with digestion and nutrient absorption, as well as immune and microbiome support; secondly, throughReduce total protein mass, to approximate the composition of breast milk; thirdly, adjusting the ratio of whey to caseinRatio broken down into 80:20, making it more similar to early breast milk to help infants absorb and digest optimized protein.

Furthermore, to further differentiate itself from the mainstream infant formula giants, ByHeart has made two attempts:

First, in terms of product ingredients, ByHeartEmphasis on Organic Raw Materials, they also received the Clean Label Project Purity Award. It is understood that all infant formula produced by ByHeart comes from grass-fed organic whole milk and contains no corn syrup, maltodextrin, soy, or palm oil. Next isUser-Centric Market EducationIn 2021, ByHeart launched the online platform Cluster, connecting parents directly with nutritional science experts and resources on infant nutrition and feeding to support parental feeding decisions from pregnancy through early childhood.

Currently, the infant formula market is fiercely competitive. On one hand, industry giants maintain a monopoly, demonstrating overwhelming market competitiveness; on the other hand, new entrants continue to emerge, resulting in a mixed and heterogeneous market environment while simultaneously driving innovative companies to strengthen their core competencies and move toward the high-end segment.

In this context, it is particularly important to become a brand that gains consumer recognition. Of course, this is inseparable from its high emphasis on product quality and continuous investment in brand building, as demonstrated by ByHeart’s development journey.

First, atHigh Barriers in Product Research and Development, which is made possible by the support of ByHeart’s team of scientists, providing robust scientific backing and theoretical research for product development. Secondly, we have establishedComplete Supplier Chain, which not only ensures the normal output of products but also helps enterprises conduct better quality screening; finally,Differentiate, accurately position itself and leverage its core strengths to enter the market.

Currently, ByHeart infant formula has already beenFDA Approval Granted, thereby achieving the commercialization of the product.